Basilea, iNtRON sign deal for antibacterial agent
Next year, Basilea will explore multiple hypotheses through preclinical studies to identify the optimal future clinical development programme for tonabacase. Under an exclusive option, Basilea will license tonabacase
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.